Stethoscope


Health care is on a collision course with patient needs and economic reality. Without significant changes in health care delivery, the scale of the problem will only get worse. Rising costs, mounting evidence of quality problems, and increasing numbers of Americans without insurance are unacceptable and unsustainable.  We can do better.

How do leaders dramatically improve value for patients and families? The most pressing task to achieve value improvement is to create a new and better structure and organization of care delivery.  These innovations must create solutions for patients and families that are far more effective and efficient than today's patchwork of services.  This improvement in value also enables increased success and professional satisfaction for clinicians, who are now accustomed to working in systems that too often impede efficacy and raise costs.  Centering care around solutions for patients will require clinically integrated interdisciplinary teams, meaningful measurement of results, and new partnerships which result in higher quality and lower cost care. 

 Doctor and Scrubs
   

 

HEALTH CARE INNOVATION PUBLICATIONS

“Improving Value: Health + Care in the UK.” Business Strategy Review, vol. 22, issue 1, 2011.

“Dinero habló con esta profesora de la Universidad de Virginia.” Dinero Magazine, August 12, 2010.

“Ein Qualitätswettbewerb senkt die kosten [Competition on Quality Lowers Costs].”  Interviewed by Urs P. Gasche, CSS Magazin, March 2009. [Translated and published simultaneously in the German, French, and Italian editions of the magazine].

“Creating a High Value Delivery System for Health Care.” Seminars in Thoracic and Cardiovascular Surgery, Spring 2009, vol. 21, no. 1, pp. 35-42. Co-authored with Scott Wallace.

“Testimony of Elizabeth Olmsted Teisberg before the Senate committee on Health, Education, Labor and Pensions." Congressional Record, January 29, 2009. Written testimony is available at: http://www.isc.hbs.edu/pdf/20090129_Tesiberg_Senate_Testimony.pdf. 

“Health Stewardship: The Responsible Path to a Healthier Nation.” by the Aspen Institute, 2009.  Co-authored with Scott Wallace, on behalf of the advisory committee for the Aspen Health Stewardship Project.

“Opportunities for Value-Based Competition in Swiss Health Care.” July 10, 2008. Published in German:  Nutzenorientierter Wettbewerb im schweizerischen Gesundheitswesen: Möglichkeiten und Chancen.

“Rethinking the Role of Employers.” Financial Times.com, July 3, 2008. Co-authored with Michael E. Porter and Scott Wallace.

“HEALTH REFORM: Redefining Health Care.” Heath Affairs Blog, March 23, 2007. Coauthored with Michael E. Porter.

“How Physicians Can Change the Future of Health Care.” Journal of the American Medical Association, JAMA. 2007;297:1103-1111, March 14, 2007. Co-authored with Michael E. Porter.

“Driving Improvement in Value for Patients.” Online Exclusive, The Cerner Quarterly, vol. 2, no. 3, 2006. http://www.cerner.com/public/CernerQuarterly.asp?id=27750.

Interview: “Michael Porter and Elizabeth Teisberg on Redefining Value in Health Care: An Interview.” Interviewed by Alistair Davidson and Robert M. Randall, Strategy and Leadership, vol. 34, no.6, 2006, pp. 48-50.

“Doctor Know: Information Is The Best Medicine.” The New Republic, July 2006. Co-authored with Michael Porter.

Redefining Health Care: Creating Value Based Competition on Results. Harvard Business School Press. May 2006. Co-authored with Michael E. Porter.

“Redefining Competition in Health Care.” Harvard Business Review, June 2004, pp. 64-77.
Co-authored with Michael E. Porter.

“Fixing Competition in U.S. Health Care.” HBR Research Report, June 2004, Product number 7081. Co-authored with Michael E. Porter.

A Script - Innovation Is the Key.  EIU Healthcare International, Economist Intelligence Unit Limited, 1st Quarter 1997, pp. 79-88. Co-authored with Gregory B. Brown.

“Building on Strength: Upgrading the Medical Device Cluster in Massachusetts.” Governor’s Council on Economic Growth and Technology, prepared for Governor Weld of Massachusetts with the assistance of Yiannis Monovoukas and Scott Wilkin, March 1995. (This work with about 15 CEOs led to the formation of Mass Medical, the state’s medical device industry association.)

“Making Competition in Health Care Work.” Harvard Business Review, July-August 1994, vol. 72, no. 4, pp. 131-141. Co-authored with Michael E. Porter and Gregory B. Brown.

“The Role of Biomedical Research in Health Care Reform.” Science, October 7, 1994. Co-authored with M.W. Kirschner and Elizabeth Marincola.

“Innovation: Medicine's Best Cost-Cutter.” Viewpoints column. The New York Times, February 27, 1994. Co-authored with Michael E. Porter and Gregory B. Brown.

“The Debate on Health Care Reform Continues.” Harvard Business Review, November-December 1994. Co-authored with Michael E. Porter and Gregory B. Brown.

“Finding a Lasting Cure for U.S. Health Care.” Perspectives column. Harvard Business Review, September-October 1994. Co-authored with Michael E. Porter and Gregory B. Brown.

STRATEGY AND REAL OPTIONS PUBLICATIONS

The Portable MBA, Fourth Edition. John Wiley & Sons, Inc., New York, 2003. Co-authored with R.F. Bruner, M.R. Eaker, R.E. Freeman, R.E. Spekman and S. Venkataraman.

“Sustainable Business: Opportunity and Value Creation.” INTERFACES, May-June 2000, 30, no. 3, pp. 1-12. Co-authored with A. Larson and R. Johnson.

Special Issue of INTERFACES on Sustainable Business. May-June 2000. Co-editor with A. Larson.

“Introduction: Strategy, Modeling and Analysis.” INTERFACES, November-December 1999, 29, no. 6, pp. 1-3. Co-authored with S. Bodily.

Special Issue of INTERFACES on Strategy, Analysis and Models. November-December 1999, 29, no. 6. Co-editor with S. Bodily.

The Portable MBA, Third Edition. John Wiley & Sons, Inc., New York, 1998. Co-authored with R.F. Bruner, M.R. Eaker, R.E. Freeman, and R.E. Spekman.
Translated into Japanese (1998), Portuguese (1999), Chinese (1999) and Russian (2000).

“Methods for Evaluating Capital Investment Decisions Under Uncertainty.” Real Options in Capital Investment: New Contributions. Edited by Lenos Trigeorgis. Westport, CT: Praeger Publishing, 1995.

“An Option Valuation Analysis of Investment Choices by a Regulated Firm.” Management Science, April 1994, vol. 40, no. 4, pp. 535-548.

“Capital Investment Strategies Under Uncertain Regulation.” The RAND Journal of Economics, Winter 1993, vol. 24, no. 4, pp. 591-604.

“The Value of Commodity Purchase contracts with Limited Price Risk.” The Energy Journal, 1991, vol. 12, no. 3, pp. 109-135. Co-authored with Thomas J. Teisberg.

“When Choosing R&D Projects, Go with Long Shots.” Research-Technology Management, January-February 1991. Co-authored with A.L. Kolbe and P.A. Morris.

“Investment Cost Recovery and Incentives for Power Plant Construction.” Public Utilities Fortnightly, March 3, 1988, vol. 121, no. 5, pp. 9-14.

“Evaluating the Effects of Time and Risk on Investment Choices: A Comparison of Finance and Decision Analysis.” Electric Power Research Institute Project, 2379-4, January 1987. Co-authored with A.L. Kolbe and P.A. Morris.

OTHER PUBLICATIONS

“Managing Ideas.” Autumn 2003. Batten Briefings. Co-authored with C. Thompson and K. Ramdas.

“Analyzing R&D and Policy Options for the Greenhouse Effect.” The Energy Industries in Transition: 1985-2000, Part I. Edited by J.P. Weyant and D.B. Sheffield, International Association of Energy Economists, 1984. Co-authored with B.R. Judd and L.J. Pollenz.


COURSE DEVELOPMENT MATERIALS

INNOVATION (INCLUDING HEALTH SECTOR INNOVATION)

Course on Value-Based Health Care Delivery developed in collaboration with Professor Michael E. Porter. (See teaching) Course development includes cases, lectures, teaching plans, teaching notes and videos of case protagonists.  The first five cases below address Redefining Health Care.

The Cleveland Clinic Growth Strategy 2008, HBS no. 9-709-473, 2009, REV. February 1, 2010
Co-authored with Michael E. Porter

The Joslin Diabetes Center, HBS no. 9-710-424, 2009, REV. January 25, 2010.
Co-authored with Michael E. Porter and Scott Wallace

 International Diabetes Center at Park Nicollet, forthcoming HBS case.
 Co-authored with Michael E. Porter

Novo Nordisk in 2009, forthcoming HBS case.
 Co-authored with Scott Wallace and Michael E. Porter

 Park Nicollet Health Services: Diabetes Care, forthcoming HBS case.
 Co-authored with Michael E. Porter

 Magnetic Surgery System (A)
December 1999, UVA-OM-0888

Magnetic Surgery System: B, C, D and E
December 1999, UVA-OM-0889, 0890, 0891 and 0892

Managing Innovation at GE Medical Systems (A)
December 1998, UVA-OM-0882

Managing Innovation at GE Medical Systems (B)
1999, UVA-OM-0883

Option Valuation: Insights and Explanations Using a Binomial Approach
July 1999, UVA-OM-0900

Seaflower Associates, Inc.: Valuing Venture Capital with Real Options
January, 1999, UVA-OM-0884

Active Coatings, Inc. (A) - Challenges in Managing Product Development
February 1996, Harvard Business School, no. 9-796-061

Active Coatings, Inc. (B) - Challenges in Managing Product Development
February 1996, Harvard Business School, no. 9-796-062

 Note on the FDA Approval Process for Medical Devices
November 1995, Harvard Business School, no. 9-796-063 13

Zoll Medical Corporation
December 1994, Harvard Business School, no. 9-795-053

Zoll Medical Corporation (B), (C) and (D)
December 1994, Harvard Business School, no. 9-795-054, no. 9-795-055, and no. 9-796-078

Alpha-Beta Technology, Inc., Pioneering Carbohydrate Technology
February, 1994, Harvard Business School, no. 9-794-093

Alpha-Beta Technology, Inc. (B): Trials with Betafectin
December, 1994, Harvard Business School, no. 9-795-045

Diagnosis for the Future: The Genetic Testing Industry in 1993
February 1994, Harvard Business School, no. 9-794-053

IG Laboratories Inc. (A): Pursuing the Future of Genetic Testing
October 1994, Harvard Business School, no. 9-794-054

IG Laboratories, Inc. (B): The Paradox of Growth – 1993-94
February 1996, Harvard Business School, no. 9-796-114

Genzyme Corporation
 April 1993, Rev. May 1994, Harvard Business School, no.9-793-120 and TN no. 5-793-122

Biotechnology Strategies in 1992
April 1992, Rev. June 1993, Harvard Business School, no.9-792-082 and TN no. 5-793-036